Introduction
Congenital heart disease (CHD) is the leading cause of infant deaths in the United States [1] and accounts for more than half of all deaths from congenital anomalies worldwide [2] . CHD represents a heterogeneous group of structural defects that arise during heart development. It is the most common type of birth defect, affecting about 8 per 1000 live births in the United States [3, 4] , approximately 25% of whom will require invasive treatment within the first year of life [5] . Bicuspid aortic valve, which is present at birth but often not detected until much later in life, affects an additional estimated 1.4% of the population [4] . Although innovations in diagnostic and management tools have led to improved detection and survival as well as an increase in the population of adults living with CHD, longterm complications such as arrhythmias and heart failure Abstract In an era of ongoing need for research to enable evidence-based care for the expanding population with congenital heart disease (CHD), economic fluctuations have impacted research funding. We characterize trends in NIHfunded CHD research from 2005 to 2015. We searched the NIH RePORTER database from 2005 to 2015 using the terms "congenital heart" and "cardiac morphogenesis". Projects were characterized by year, institute, mechanism, costs, type and topic, and funding trends were analyzed. From 2005 to 2015, NIH funded 633 CHD research projects with total costs of $991 million. The National Heart, Lung, and Blood Institute funded 83% of CHD projects (528, $857 million). The R01 mechanism was used for 45% of projects (288, $421 million). Projects were 70% basic/ early translational research, 27% clinical research, and 3% both. Cardiac developmental biology was the most common topic (52%), followed by technology/therapy development (15%), and diagnosis/management (12%). The total number of CHD projects ranged from 153 to 221 per year (30-58 new projects/year), and costs per year ranged from $58 to $116 million. The number of projects and total costs increased until 2012, but decreased again thereafter. CHD research did not experience as much erosion as overall NIH purchasing power; in constant dollars, CHD research funding levels in 2015 were $12 million higher than those in 2005. The NIH supported a diverse portfolio of CHD projects from 2005 to 2015. Support of CHD research projects trended upward until 2012, but declined thereafter due to fiscal austerity measures. remain a challenge, particularly for complex lesions. CHDrelated hospital discharge mortality is the highest among neonates (10%) [5] but is also substantial among adults with CHD (2-5%) [5, 6] . Resource utilization is high for individuals with CHD [7] [8] [9] [10] , particularly among those requiring cardiovascular surgery.
Descriptions of CHD and endeavors to understand cardiac development began hundreds of years ago, but the first classification scheme for CHD was proposed in 1858 by Thomas Peacock. Maude Abbott's 1908 chapter on "congenital cardiac disease" echoed Peacock's sentiment that CHD is likely caused by arrested cardiac development. The surgical era of CHD began in 1939 with Robert Gross' first patent ductus arteriosus ligation, followed in 1944 by the blue baby operation for tetralogy of Fallot championed by Helen Taussig, Alfred Blalock, and Vivien Thomas [11] . The National Institutes of Health (NIH) has a long track record of support for research in CHD; in fact, Blalock received NIH funding in 1949 for his pioneering work on CHD. Since then, researchers have uncovered vital insights into disease mechanisms and have developed many novel treatment strategies. The results of NIH investments in CHD research are apparent through improving outcomes and a multitude of publications from prolific scientists, yet much remains to be done. The persistent burden of disease, the growing population of survivors with CHD, and the rising costs of their healthcare underscore the importance of research in understanding the mechanisms of abnormal cardiac development and translating those findings into evidence-based preventative, diagnostic, and therapeutic strategies to guide care.
Over the last decade, funding levels for NIH research have been relatively flat, and starting in 2013, automatic spending cuts resulted in a 5.5% decrease in the NIH budget. Such budget cuts combined with the effects of inflation resulted in an erosion of purchasing power by almost 25% for biomedical research at NIH over the past decade [12] . It is unclear how this erosion has impacted research in CHD because descriptions of the NIH's financial allocations to CHD funding have not been published previously. The purpose of this study was to analyze the NIH research portfolio to characterize trends in investments in CHD research over the past decade.
Methods
The NIH Research Portfolio Online Reporting Tools (RePORT) system is a publicly available searchable website that provides access to reports, data, and analyses of research funded by NIH. The system contains information on NIH-funded intramural and extramural research projects since 1989 [13] . The database is organized by research, condition, and disease categorization codes. In 2015, a specific code for CHD was created, but prior to 2015, CHD projects were classified under cardiovascular disease.
In the absence of a code for CHD prior to 2015, we searched one of the modules within RePORT, the Research Portfolio Online Reporting Tools Expenditures and Results (RePORTER) database of NIH-funded projects for active grants and contracts between 2005 and 2015 using the search terms "congenital heart" and "cardiac morphogenesis". The search terms needed to be present in the title, abstract, specific aims, or public health relevance section of the application. We excluded projects on cardiomyopathy, arrhythmia, and pulmonary hypertension, unless the research focused on these entities in the setting of CHD. We also excluded projects on genetic syndromes if the research was not focused on the cardiac manifestations, as well as research on generalized organogenesis that was not specific to the heart. We cross-checked our internal portfolio to identify projects that may have been missed by our search terms.
After manually filtering out non-CHD related projects, each project was characterized by year, awarding institute, funding mechanism, funding announcement, and total costs per year. We categorized each project by type: clinical research, basic/early translational research, or both (e.g., training grants often include both clinical and basic/early translational research exposure). Among clinical research projects, we identified the clinical trials. We then classified each project by the following topic areas: cardiac developmental biology, diagnosis/management, epidemiology, human genetics, physiology, therapy/technology development or multiple topics. Discrepancies were adjudicated among the authors.
NIH definitions were used to describe grants; contracts; basic, early translational, and clinical research; and clinical trials [14] . NIH funding mechanisms were grouped into the following categories: research project grants, career development/training grants, small business projects (SBIR/ STTR), intramural research performed on the NIH campus, contracts, and other less-common research support mechanisms (e.g., conference, resource, and challenge grants, high-impact research grants and biomedical research support shared instrumentation grants). The research project grant category included investigator-initiated research projects (R01), program project grants involving multiple research projects (P), exploratory research grants (R21), small research grants (R03), academic research enhancement awards (AREA-R15), research transition awards (R00), planning grants (R34), method to extend research in time grants (MERIT-R37), bridge awards (R56), linked research project grants (RL1), and cooperative agreements (U) requiring significant NIH staff involvement. The career development/training category included career 1 3 development awards (K), fellowship grants (F), early independence grants (DP5), and institutional training grants (T).
Descriptive statistics were used to characterize the number of projects and awards, amount of funding, institute, mechanism, category, topic, and trends over time. The Consumer Price Index calculator was used to calculate constant 2005 dollars from current dollars [15] . Data analysis was performed using Microsoft Excel 2016.
Results
The RePORTER search identified 1074 projects, of which 441 were excluded as described above or for lack of relevance. (Fig. 1 ) Thus, 633 CHD research projects were funded by NIH from 2005 to 2015 at a total cost of $991 million. The National Heart, Lung, and Blood Institute (NHLBI) supported the majority of CHD projects (83%, 528 projects, $857 million), followed by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (8%, 48 projects, $86 million).
Funding mechanisms focused on fostering the next generation of scientists, including career development, fellowship, early independence, and institutional training grants, made up a total of 23% of all CHD projects (144 projects, $60 million). Research project grants made up 66% of projects (419 projects, $776 million). (Fig. 2a) The most common funding mechanism was the investigator-initiated R01 research project grant (288 projects, $421 million), while cooperative agreement (U) mechanisms made up 49 projects ($235 million). Most of these cooperative agreements represent institute initiatives designed to stimulate multicenter, collaborative research, such as the NHLBI Bench to Bassinet Program, comprised of the Pediatric Heart Network (PHN), the Pediatric Cardiac Genomics Consortium, and the Cardiovascular Development Consortium. Others represent large clinical trials that required significant NHLBI staff involvement.
Early-stage investigators and new investigators led 65 projects (30% of the eligible R01 and DP2 grants). Investigator-initiated projects made up 80% of CHD research (505 projects, $555 million), whereas 20% of CHD projects (128 projects, $437 million) were funded in response to NIH initiatives or as intramural projects carried out on the NIH campus.
From 2005 to 2015, NIH funded 441 basic/early translational research projects (70%, $595 million), 172 clinical research projects (27%, $372 million), and 20 projects involving both basic/early translational and clinical research (3%, $24 million). (Fig. 2b ) Among clinical Fig. 1 Search results. This figure demonstrates the results of the NIH RePORTER database search using the terms "congenital heart" or "cardiac morphogenesis". CHD research projects were categorized by mechanism, type, and topic, and were characterized by number of projects and total costs. CHD congenital heart disease, NIH National Institutes of Health, RePORTER Research Portfolio Online Reporting Tools Expenditures and Results research projects, ten investigator-initiated CHD clinical trials were funded from 2005 to 2015 outside of NIH networks. Within NIH networks, 37 grants ($101 M) were awarded to conduct CHD research. Cardiac developmental biology was the most prevalent area of CHD research (52%, 328 projects, $401 million), followed by technology/ therapy development (15%, 96 projects, $165 million) and diagnosis/management (12%, 78 projects, $187 million) (Fig. 2c) .
The 
Discussion
Our analysis provides an important snapshot of NIH investments in CHD research over the past decade, and our results will facilitate future comparisons with projects categorized under the NIH Research, Condition, and Disease Categorization code for CHD that was created in 2015. We demonstrate a significant investment in CHD research by NIH from 2005 to 2015 through a robust portfolio of research projects. The high proportion of basic/early translational CHD projects provides a rich knowledge base that is ripe for translation to clinical trials. Funding for CHD research increased over time until 2012, but decreased thereafter in the setting of fiscal austerity measures. Yet CHD research did not experience as much erosion as overall NIH funding over the past decade. Consistent with research in other diseases [16, 17] , investigator-initiated R01 grants are the mainstay of NIH support for CHD research. Creative ideas from innovative scientists will continue to provide a breadth and depth to CHD research necessary to advance a field known for its heterogeneous lesions, ages, and outcomes. Our data also demonstrate the NIH's consistent commitment to training the next generation of scientists through its distribution of nearly one quarter of CHD projects towards career development, fellowship, and training mechanisms.
We noted a higher number of basic/early translational projects than clinical research projects in CHD. Similar trends have been seen in an analysis of NIH-funded research on hypertension [18] . In the mid-1980s, Constance Weinstein, a program official at the NHLBI, acknowledged the importance of basic research in cardiac development to inform the biological basis of CHD by initiating a series of requests for applications to stimulate science in that area. A vibrant research community has grown out of those efforts. Many of the findings from this basic science research have relevance not only to CHD, but to cardiovascular disease more broadly. For example, research on cardiomyocyte development and proliferation has informed research on stem cell therapy for ventricular dysfunction after myocardial infarction.
To maximize health impact and the return on investments made in CHD research, it is essential to also support clinical trials that help translate fundamental discoveries and insights from basic/early translational research to clinical and public health practice. Bourgeois examined several high disease burden conditions among children in high-, middle-, and low-income countries and found that 60% of disease burden was attributable to children, but only 12% of studies in ClinicalTrials.gov were pediatric trials [19] . Hill's analysis of the portfolio on ClinicalTrials.gov [20] revealed a low number (116) of pediatric cardiovascular clinical trials relative to 2561 adult cardiovascular trials. Of the pediatric cardiovascular trials identified, approximately one-third were focused on diseases that may be amenable to testing a new drug, such as hypertension and dyslipidemia, rather than CHD. Hill also found that the number of pediatric cardiovascular trials was low compared to that of other pediatric conditions, including cancer.
To Trends in the number of projects and total costs for NIHfunded CHD research increased from 2005 to 2012, with an additional boost in funding provided by the ARRA economic stimulus package. But the trend took a concerning downturn in 2013, coincident with the implementation of automatic federal spending cuts called sequestration. In the face of fiscal limitations, NHLBI has prioritized increasing its funding pay line for investigator-initiated applications. Our analysis reveals increasing trends in funding new investigator-initiated CHD applications in 2014 and 2015, reflecting this focus. Reassuringly, funding for CHD research has not experienced as much of a decline over the last decade compared overall NIH funding.
In this time of fiscal austerity, NHLBI staff members have used a myriad of approaches to ensure ongoing support of the science, including conducting portfolio analyses such as this and undertaking a recent strategic visioning process. These exercises provide an opportunity to identify and prioritize high impact research areas in CHD that lend themselves to rapid translation from the bench to the bedside.
Our study should be interpreted in light of its limitations. The authors' assignment of categories was subjective, but discrepancies were adjudicated among multiple authors. In addition, using isolated search terms "congenital heart" and "cardiac morphogenesis" may not have captured all projects that are related to CHD research and may have underestimated studies of cardiac developmental biology. Initial attempts at using the search term "cardiac development" resulted in far too many false positive results, so we opted for the narrower term of "cardiac morphogenesis". We recognize that no search strategy would return results with 100% sensitivity and specificity; therefore, we attempted to balance comprehensiveness with a search strategy that was simple, consistent, and could be replicated. Although the creation of an NIH Research, Condition, and Disease Categorization code for CHD in 2015 will help to more comprehensively identify CHD research projects in the future, investigators should also consider standardization of keyword terminology for CHD research to improve reporting.
Conclusions
The NIH demonstrates an ongoing and significant commitment to CHD research through substantial support for basic/early translational and clinical projects via a variety of mechanisms. Although previous increases in CHD research funding levels have been hampered by recent fiscal austerity measures, CHD research funding has been maintained despite economic fluctuations. Future efforts should focus on funding science with high potential for translation of findings from the bench to the bedside.
